Internal Medicine, Hematology & Oncology · McAllen, TX
NPI
1174599948
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
5401 N G St Ste 300
McAllen, TX, 78504
Phone (956) 217-7000
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.5M
104,751 services
Medicare patients, 2024
146
Average age 72
Drug cost, 2024
$20.5M
4,905 prescriptions
Company payments, 2025
$3,388
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Eugenio G Galindo was code J0897 (injection, denosumab, 1 mg), 5,820 times for 17 patients. In total Eugenio G Galindo billed 104,751 services in 88 codes, and Medicare paid $1.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-03-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 5,820 | 17 | $20.54 | $120K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 4,270 | 25 | $0.10 | $442 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,430 | 22 | $0.09 | $129 |
| 36415 Venipuncture Blood Collection | Office | 737 | 144 | $8.65 | $6,375 |
| 85025 Blood Count | Office | 708 | 143 | $7.61 | $5,388 |
| 88185 Surgical Pathology Examination | Office | 390 | 15 | $17.39 | $6,784 |
| 96367 Intravenous Infusion, Hydration | Office | 362 | 23 | $21.16 | $7,661 |
| 96372 Injection Administration | Office | 323 | 40 | $10.35 | $3,344 |
| 99214 Office E&M - Established | Office | 283 | 95 | $94.25 | $27K |
| 99213 Office E&M - Established | Office | 222 | 111 | $59.88 | $13K |
| 96415 Chemotherapy Administration | Office | 221 | 14 | $20.39 | $4,505 |
| 96413 Chemotherapy Administration | Office | 198 | 19 | $93.74 | $19K |
| 96417 Chemotherapy Administration | Office | 115 | 11 | $46.45 | $5,342 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 71 | 18 | $0.64 | $45.18 |
| 96366 Intravenous Infusion, Hydration | Office | 63 | 17 | $15.25 | $961 |
By year: 2022 $1.3M for 80,946 services; 2023 $1.1M for 91,761 services; 2024 $1.5M for 104,751 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 737 | 144 | $8.65 | $6,375 |
| 85025 Blood Count | 708 | 143 | $7.61 | $5,388 |
| 88185 Surgical Pathology Examination | 390 | 15 | $17.39 | $6,784 |
| 88184 Surgical Pathology Examination | 15 | 15 | $55.39 | $831 |
Medicare prescription drug claims, 2024
In 2024, the drug Eugenio G Galindo prescribed most often to Medicare patients was Letrozole, with 355 prescriptions and refills. In total Eugenio G Galindo wrote 4,905 Medicare prescriptions that cost $20.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 355 | 457 | 57 | $4,166 |
| Xgeva Denosumab | 278 | 278 | 28 | $849K |
| Lupron Depot Leuprolide Acetate | 224 | 645 | 60 | $1.3M |
| Xtandi Enzalutamide | 206 | 206 | 19 | $2.8M |
| Procrit Epoetin Alfa | 191 | 208 | 36 | $207K |
| Exemestane Generic | 191 | 284 | 32 | $19K |
| Prednisone Generic | 171 | 171 | 31 | $338 |
| Erleada Apalutamide | 169 | 169 | 16 | $2.4M |
| Abiraterone Acetate Generic | 169 | 169 | 27 | $525K |
| Dexamethasone Sodium Phosphate Generic | 158 | 158 | 32 | $872 |
| Megestrol Acetate Generic | 130 | 140 | 28 | $17K |
| Kisqali Ribociclib Succinate | 108 | 108 | 16 | $1.5M |
| Prolia Denosumab | 103 | 618 | 56 | $166K |
| Imbruvica Ibrutinib | 102 | 102 | Under 11 | $1.6M |
| Ondansetron Odt Ondansetron | 101 | 101 | 30 | $1,663 |
Brand drugs: 2,353 claims; generic drugs: 2,552 claims; opioid claims: 70.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Eugenio G Galindo $3,388 ($3,388 in general payments such as food, travel and fees) from 33 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,282.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 29 | $1,282 |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $299 |
| Janssen Biotech, Inc. JNJ | 10 | $293 |
| Pfizer Inc. PFE | 18 | $165 |
| Genentech USA, Inc. ROG.SW | 6 | $138 |
| Celgene Corporation BMY | 5 | $124 |
| Kite Pharma, Inc. GILD | 5 | $116 |
| Rigel Pharmaceuticals, Inc. RIGL | 5 | $94.32 |
| Daiichi Sankyo Inc. 4568.T | 3 | $65.86 |
| Puma Biotechnology, Inc. PBYI | 3 | $63.24 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.